Browsing Category

Toxicology

General Information, Toxicology

Test Discontinuation: Drug of Abuse Screen, Pain Clinic, Urine

Effective September 1, 2019, the test Drug of Abuse Screen, Pain Clinic, Urine will be discontinued.

Earlier this year, Spectrum Health Regional Laboratory – Toxicology announced two new drug screen panels, Urine Drug Screen with Confirmation (23 Targets) and Urine Drug Screen with Confirmation (32 Targets) as replacement tests. For more information regarding these new tests please reference this post. Continue Reading

Referral/Sendouts, Toxicology

Toxicology Testing Updates – May 2018

As of May 8, 2018, the following tests are no longer performed by Spectrum Health Laboratory. These tests are now available through Mayo Medical Laboratories as a send out. Please note that the specimen collection for these tests may have changed. Please check the Laboratory Catalog for collection information.

Discontinued Test Code Discontinue Test Name Replacement Code Replacement Name
LAB752 Clomipramine Level LAB1230481 Clomipramine, Serum
LAB683 Ethosuximide Level LAB1230480 Ethosuximide, Serum

Questions may be directed to the Toxicology Department using the “Contact Us” link above.

Compliance & Safety, Toxicology

Urgent Notice: Lead Testing

On May 17, 2017, the US Food and Drug Administration (FDA) issued a safety communication warning against using venous samples on Point of Care Magellan Diagnostics LeadCare Testing System devices (LeadCare, LeadCare II, LeadCare Plus, and LeadCare Ultra). Venous specimens appear to be at risk for having falsely low results.  Only Capillary (“finger stick” or “heel stick”) specimen types should be used.

IF YOUR OFFICE IS USING ANY OF THE MAGELLAN LEADCARE TESTING SYSTEM DEVICES: please DISCONTINUE the use of VENOUS specimens for testing. Continue Reading

Test Utilization, Toxicology

Vitamin D 1,25 Testing

Numerous 1,25-Dihydroxyvitamin D (1,25(OH)2D) requests are received daily (1200 in 2015). This is not the standard test for Vitamin D status.  1,25-Dihydroxyvitamin D testing should be reserved for patients with renal disease, sarcoid, tuberculosis, lymphoma and rickets, as well as, long term use of protease inhibitors, glucocorticoids, or anticonvulsants. Vitamin D 25 (25 OH D) level is sufficient in most cases. The number of requests and review of the ordering providers raises a concern that a number of these requests were ordered inappropriately.

In an effort to decrease the number of potential improperly ordered tests and consequently decrease unnecessary costs to patients, insurance companies, and the laboratory, please review your individual ordering practices.

In the near future, this test name will be changed to “Renal 1,25 Dihydroxyvitamin D” to better reflect its appropriate utilization.

Any questions concerning Vitamin D testing may be directed to the Pathology Department.